trending Market Intelligence /marketintelligence/en/news-insights/trending/88qGnA6vHU5MfUqOWRBV5A2 content esgSubNav
In This List

CSL's autoimmune drug granted US FDA's orphan drug designation

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


CSL's autoimmune drug granted US FDA's orphan drug designation

CSL Ltd.'s autoimmune disorder medicine has been granted orphan drug designation by the U.S. Food and Drug Administration.

The regulator's decision on CSL's Hizentra provides for a seven-year period of marketing exclusivity in the U.S. as a maintenance therapy to prevent the return of chronic inflammatory demyelinating polyneuropathy in certain adult patients. The disorder targets the peripheral nerves and may cause permanent nerve damage.

The FDA grants the designation for medications that treat rare diseases affecting fewer than 200,000 patients in the U.S.

Hizentra is already approved in Japan and the U.S. to prevent relapse of chronic inflammatory demyelinating polyneuropathy in adults. Additionally, the drug is approved in over 50 countries to treat certain immune deficiencies.